<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H4E401B1F085543F9B84E6356E460B9D5" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 1796 IH: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-03-03</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1796</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250303">March 3, 2025</action-date><action-desc><sponsor name-id="J000307">Mr. James</sponsor> (for himself, <cosponsor name-id="V000131">Mr. Veasey</cosponsor>, <cosponsor name-id="C001125">Mr. Carter of Louisiana</cosponsor>, <cosponsor name-id="D000096">Mr. Davis of Illinois</cosponsor>, and <cosponsor name-id="K000399">Mrs. Kiggans of Virginia</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.</official-title></form><legis-body id="H073159048A0B4147B4FF00CAB277DE67" style="OLC"><section id="HB3209A0F92964D8787110553C9D8D800" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025</short-title></quote>.</text></section><section commented="no" display-inline="no-display-inline" id="HB9240117D3BE47E0AE178D366AD58A47"><enum>2.</enum><header>Sickle cell disease treatment prevention and treatment</header><subsection commented="no" display-inline="no-display-inline" id="HD0E2ECC42AB7465EBDDC98923265F98F"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Section 1106(b) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300b-5">42 U.S.C. 300b–5(b)</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="H1699B8618E4745EC98C367E7E01374C3"><enum>(1)</enum><text>in paragraph (1)(A)(iii), by striking <quote>prevention and treatment of sickle cell disease</quote> and inserting <quote>treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease</quote>;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H41C2D3E27E1045F2AF30ED34C4A26636"><enum>(2)</enum><text>in paragraph (2)(D), by striking <quote>prevention and treatment of sickle cell disease</quote> and inserting <quote>treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease</quote>;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HEAFE677D9650411C998A0A2A897A8185"><enum>(3)</enum><text display-inline="yes-display-inline">in paragraph (3)—</text><subparagraph commented="no" display-inline="no-display-inline" id="HA2FF381A294B48E9AC715F524B6AB66F"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (A), by striking <quote>enter into a contract with</quote> and inserting <quote>make a grant to, or enter into a contract or cooperative agreement with,</quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HC7C583AEE4C6406A93DA56BD2BF3114D"><enum>(B)</enum><text>in subparagraph (B), in each of clauses (ii) and (iii), by striking <quote>prevention and treatment of sickle cell disease</quote> and inserting <quote>treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease</quote>; and</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H1C50D1C38B1145F39CEDA6157D9B2CFE"><enum>(4)</enum><text>in paragraph (6), by striking <quote>$4,455,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$8,205,000 for each of fiscal years 2025 through 2029</quote>.</text></paragraph></subsection><subsection id="H7EADDCEFFEC84FA9A7A342B53B36A445"><enum>(b)</enum><header>Sense of Congress</header><text>It is the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease.</text></subsection></section></legis-body></bill> 

